EUVIMEDEUVIMED entdecken
Open Access

Dual‑regulated oncolytic adenovirus carrying ERCC1 ‑siRNA gene possesses potent antitumor effect on ovarian cancer cells

Ting Zhao, Wei Ye, Rui Zhang, Xiaoyan Zhu, Qin Shi, Xiaofeng Xu, Weifeng Chen, Ling Xu, Yaping Meng

Molecular Medicine Reports · 2024

DOI: 10.3892/mmr.2024.13245 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Medicine Reports, 2024. Verfasst von Ting Zhao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Jiading District Central Hospital Affiliated Shanghai University of Medicine and Health Sciences, Shanghai 2…. Hauptthemen laut MEDLINE: Adenoviridae, DNA-Binding Proteins, Endonucleases, Oncolytic Viruses. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian cancer is a multifactorial and deadly disease. Despite significant advancements in ovarian cancer therapy, its incidence is on the rise and the molecular mechanisms underlying ovarian cancer invasiveness, metastasis and drug resistance remain largely elusive, resulting in poor prognosis. Oncolytic viruses armed with therapeutic transgenes of interest offer an attractive alternative to chemical drugs, which often face innate and acquired drug resistance. The present study constructed a novel oncolytic adenovirus carrying ERCC1 short interfering (si)RNA, regulated by hTERT and HIF promoters, termed Ad‑siERCC1. The findings demonstrated that this oncolytic adenovirus effectively inhibits the proliferation, migration and invasion of ovarian cancer cells. Furthermore, the downregulation of ERCC1 expression by siRNA ameliorates drug resistance to cisplatin (DDP) chemotherapy. It was found that Ad‑siERCC1 blocks the cell cycle in the G1 phase and enhances apoptosis through the PI3K/AKT‑caspase‑3 signaling pathways in SKOV3 cells. The results of the present study highlighted the critical effect of oncolytic virus Ad‑siERCC1 in inhibiting the survival of ovarian cancer cells and increasing chemotherapy sensitivity to DDP. These findings underscore the potent antitumor effect of Ad‑siERCC1 on ovarian cancers in vivo.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenoviridaeDNA-Binding ProteinsEndonucleasesOncolytic VirusesOvarian NeoplasmsRNA, Small InterferingFemaleHumansAntineoplastic AgentsApoptosisCell Line, TumorCell MovementCell ProliferationCisplatinDrug Resistance, NeoplasmGenetic VectorsOncolytic VirotherapyPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal Transduction

Stichwörter der Autor:innen

ERCC1adenovirushTERT/HIFovarian cancerproliferation

Substanzen

Antineoplastic AgentsCisplatinDNA-Binding ProteinsEndonucleasesERCC1 protein, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRNA, Small Interfering

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Jiading District Central Hospital Affiliated Shanghai University of Medicine and Health Sciences, Shanghai 201800, P.R. China.

Zitieren

APA

Zhao, T., Ye, W., Zhang, R., Zhu, X., Shi, Q., Xu, X., Chen, W., Xu, L., & Meng, Y. (2024). Dual‑regulated oncolytic adenovirus carrying ERCC1 ‑siRNA gene possesses potent antitumor effect on ovarian cancer cells. Molecular Medicine Reports. https://doi.org/10.3892/mmr.2024.13245

Vancouver

Zhao T, Ye W, Zhang R, Zhu X, Shi Q, Xu X, et al. Dual‑regulated oncolytic adenovirus carrying ERCC1 ‑siRNA gene possesses potent antitumor effect on ovarian cancer cells. Molecular Medicine Reports. 2024. doi:10.3892/mmr.2024.13245

BibTeX
@article{Zhao2024,
  author = {Zhao, Ting and Ye, Wei and Zhang, Rui and Zhu, Xiaoyan and Shi, Qin and Xu, Xiaofeng and Chen, Weifeng and Xu, Ling and Meng, Yaping},
  title = {Dual‑regulated oncolytic adenovirus carrying ERCC1 ‑siRNA gene possesses potent antitumor effect on ovarian cancer cells},
  journal = {Molecular Medicine Reports},
  year = {2024},
  doi = {10.3892/mmr.2024.13245}
}
Kostenlos starten →